In mid-2024, the Endocrine Society warned that online prescribing of compounded GLP-1s poses patient safety risks and undermines public confidence in obesity care. The organization called for stricter verification of clinicians and for oversight of digital compounding networks that have limited traceability or pharmacovigilance. Their concern echoed that of the FDA , which, after investigating multiple adverse-event reports linked to unapproved semaglutide, issued formal warnings to both compounders and telehealth distributors
No controlled study has established a KLOW results timeline
Some other studies have suggested that, though IF might have little effect on inflammation, it may greatly influence oxidative stress, which is linked to insulin resistance (26)
The absence of these peptides makes it less affinity to IGFBPs, thus more effective because it will stay in the host body long enough to exert the desired pharmacological actions
Nguyen H, Dufour R, Caldwell-Tarr A